Lung infections associated with cystic fibrosis

Clinical Microbiology Reviews

Volumn 15, Issue 2, 2002, Pages 194-222

  Lyczak, Jeffrey B ^a   Cannon, Carolyn L ^a   Pier, Gerald B ^a  

^a CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CEFALEXIN; CEFALOTIN; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DICLOXACILLIN; IMIPENEM; NAFCILLIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL OVERGROWTH; BIOFILM; CLINICAL EXAMINATION; CYSTIC FIBROSIS; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HOST SUSCEPTIBILITY; HUMAN; IMMUNOREACTIVITY; INFECTION SENSITIVITY; LUNG CLEARANCE; LUNG INFECTION; PATHOPHYSIOLOGY; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS;

BACTERIAL INFECTIONS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HAEMOPHILUS INFLUENZAE; HISTORY, 20TH CENTURY; HUMANS; LUNG; MUTATION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 0036225688     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.15.2.194-222.2002     Document Type: Review

References (353)

1. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
2. Vfr controls quorum sensing in Pseudomonas aeruginosa
3. Nutritional supplementation in treatment of cystic fibrosis of the pancreas
4. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread
5. Cystic fibrosis of the pancreas and its relation to celiac disease: A clinical and pathologic study
6. Celiac syndrome: Genetics of cystic fibrosis of pancreas with consideration of etiology
7. Nucleoside triphosphates are required to open the CFTR chloride channel
8. Generation of cAMP-activated chloride currents by expression of CFTR
9. Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis
10. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis
11. Further studies on the pathogenesis of fibrocystic disease of the pancreas
12. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung
13. Aspergillus antibody in patients with cystic fibrosis
14. Selective pressure of antistaphylococcal chemotherapeutics in favour of Pseudomonas aeruginosa in cystic fibrosis
15. Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)
16. Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel
17. Mutational analysis of the yeast a-factor transporter STE6, a member of the ATP binding cassette (ABC) protein superfamily
18. Dietary supplement and nutrition in children with cystic fibrosis
19. Genetic and geographical variability in cystic fibrosis: Evolutionary considerations
20. The pathology of fungal infection and colonization in patients with cystic fibrosis
21. Lactate and bicarbonate uptake in the sweat duct of cystic fibrosis and normal subjects
22. Protease-anti-protease imbalance in the lungs of children with cystic fibrosis
23. Gene expression in Pseudomonas aeruginosa: Evidence of iron override effects on quorum sensing and biofilm-specific gene regulation
24. Altered respiratory epithelial cell cytokine production in cystic fibrosis
25. Mucoid Pseudomonas aeruginosa in cystic fibrosis: Characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection
26. + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation
27. Isolation of rapidly growing mycobacteria in patients with cystic fibrosis
28. Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbations of cystic fibrosis: A cross-over randomized study
29. Regulation of cortical structure by the ezrin-radixinmoesin protein family
30. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis
31. Synthesis of multiple exoproducts in Pseudomonas aeruginosa is under the control of Rh1R-Rh1I, another set of regulators in strain PAO1 with homology to the autoinducer-responsive LuxR-LuxI family
32. Differences in the concentrations of small, anionic, antimicrobial peptides in bronchoalveolar lavage fluid and in respiratory epithelia of patients with and without cystic fibrosis
33. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms
34. Transferable drug resistance in Pseudomonas aeruginosa
35. Overproduction of the CFTR R domain leads to increased levels of asialoGM1 and increased Pseudomonas aeruginosa binding by epithelial cells
36. Quinolone arthropathy in animals versus children
37. Defining potential targets for immunotherapy in Burkholderia cepacia infection
38. Microbiology of sputum from patients at cystic fibrosis centers in the United States
39. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis
40. Invasion of respiratory epithelial cells by Burkholderia (Pseudomonas) cepacia
41. Precipitins to Klebsiella and other enterobacteria in the serum of patients with chronic respiratory disorders
42. Bacterial precipitins in serum of patients with cystic fibrosis
43. Mucoid Pseudomonas aeruginosa resists nonopsonic phagocytosis by human neutrophils and macrophages
44. Identification of the cystic fibrosis transmembrane conductance regulator domains that are important for interactions with ROMK2
45. The geographical distribution of Salmonella typhi and Sabnonella paratyphi A and B phage types during the period 1 January 1966 to 31 December 1969
46. Epithelial sodium channel related to proteins involved in neurodegeneration
47. A cAMP-regulated chloride channel in lymphocytes that is affected in cystic fibrosis
48. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel
49. Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis
50. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
51. Extracellular UTP stimulates electrogenic bicarbonate secretion across CFTR knockout gallbladder epithelium
52. Allergic bronchopulmonary aspergillosis
53. Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens
54. Cystic fibrosis
55. Pili binding to asialo-GM1 on epithelial cells can mediate cytotoxicity or bacterial internalization by Pseudomonas aeruginosa
56. Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men with congenital bilateral absence of the vas deferens
57. Mycobacterium abscessus infection in cystc fibrosis. Colonization of infection?
58. The genetic advantage hypothesis in cystic fibrosis heterozygotes: A murine study
59. Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils
60. Cystic fibrosis Delta F508 heterozygotes, smoking, and reproduction: Studies of 9141 individuals from a general population sample
61. Cloning of genes controlling alginate biosynthesis from a mucoid cystic fibrosis isolate of Pseudomonas aeruginosa
62. Drug resistance and R factors in the bowel bacteria of London patients before and after admission to hospital
63. The involvement of cell-to-cell signals in the development of a bacterial biofilm
64. Cystic fibrosis
65. 1 is a receptor for Pseudomonas aeruginosa adherence to regenerating respiratory epithelial cells
66. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection
67. Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia
68. Control of mucoidy in Pseudomonas aeruginosa: Transcriptional regulation of algR and identification of the second regulatory gene, algQ
69. In vitro phosphorylation of AlgR, a regulator of mucoidy in Pseudomonas aeruginosa, by a histidine protein kinase and effects of small phospho-donor molecules
70. Mucoid-to-nonmucoid conversion in alginate-producing Pseudomonas aeruginosa often results from spontaneous mutations in algT, encoding a putative alternate sigma factor, and shows evidence for autoregulation
71. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells
72. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8
73. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas: Clinical significance and relationship to the disease
74. Celiac syndrome. IV. Chemotherapy in infection of the respiratory tract associated with cystic fibrosis of the pancreas
75. An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreas
76. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus
77. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis
78. Distribution and transmission of Pseudomonas aeruginosa and Hurkholderia cepacia in a hospital ward
79. Cystic fibrosis with three mutations in the cystic fibrosis transmembrane conductance regulator gene
80. - channels by protein kinase A corrected by insertion of CFTR
81. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
82. Coupled secretion of chloride and mucus in skin of Xenopus laevis: Possible role for CFTR
83. Submucosal glands are the predominant site of CFTR expression in the human bronchus
84. A candidate for the cystic fibrosis locus isolated by selection for methylation-free islands
85. Improving the ketchup bottle method with positive expiratory pressure, PEP, in cystic fibrosis
86. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis
87. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury
88. Source of Pseudomonas cepacia: Ribotyping of isolates from patients and from the environment
89. The changing epidemiology of cystic fibrosis
90. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
91. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
92. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice
93. Fatty acids in cystic fibrosis
94. Functional conservation of the effector protein translocators PopB/YopB and PopD/YopD of Pseudomonas aeruginosa and Yersinia pseudotuberculosis
95. Sodium-coupled chloride transport by epithelial tissues
96. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
97. Alginate synthesis in mucoid Pseudomonas aeruginosa: A chromosomal locus involved in control
98. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model
99. CFTR and outward rectifying chloride channels are distinct proteins with a regulatory relationship
100. Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis
101. Antimicrobial therapy against Staphylococcus aureus. Pseudomonas aeruginosa, and Pseudomonas cepacia
102. The spectrum of pulmonary aspergillosis
103. Delta F508 CFTR localizes in the endoplasmic reticulum-Golgi intermediate compartment in cystic fibrosis cells
104. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis
105. Rodent zoonoses in North Queensland: The occurrence and distribution of zoonotic infections in North Queensland rodents
106. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis
107. Rational parameters for antibiotic therapy in patients with cystic fibrosis
108. Microbiology of lung infection in cystic fibrosis
109. CD95/CD95 ligand interactions on epithelial cells in host defense to Pseudomonas aeruginosa
110. Interchangeability and specificity of components from the quorum-sensing regulatory systems of Vibrio fischeri and Pseudomonas aeruginosa
111. Agricultural plants and soil as a reservoir for Pseudomonas aeruginosa
112. + conductance of rat colonic crypt cells is suppressed by forskolin
113. CFTR-independent ATP release from epithelial cells triggered by mechanical stimuli
114. Pili and lipopolysaccharide of Pseudomonas aeruginosa bind to the glycolipid asialo GM1
115. + exchanger regulatory factor family of PDZ proteins
116. Pseudomonas aeruginosa isolates from patients with cystic fibrosis: A class of serum-sensitive, nontypeable strains deficient in lipopolysaccharide O side chains
117. Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding
118. Treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin
119. Prospective study of mycobacterial infections in patients with cystic fibrosis
120. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis
121. Acid-stimulated duodenal bicarbonate secretion involves a CFTR-mediated transport pathway in mice
122. - secretion
123. Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients
124. The C5a chemoattractant receptor mediates mucosal defence to infection
125. Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis
126. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years
127. Frequency of the F508 deletion in the CFTR gene in Turkish cystic fibrosis patients
128. - channels in CF: Lack of activation by protein kinase C and cAMP-dependent protein kinase
129. 3
130. cAMP and genistein stimulate HCO3-conductance through CFTR in human airway epithelia
131. Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator
132. Vaccination against typhoid fever: Present status
133. Drug resistance and R factors in P. aeruginosa
134. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
135. A test of the heterozygote-advantage hypothesis in cystic fibrosis carriers
136. Cystic fibrosis transmembrane conductance regulator is required for protein kinase A activation of an outwardly rectified anion channel purified from bovine tracheal epithelia
137. Interaction between cystic fibrosis transmembrane conductance regulator and outwardly rectified chloride channels
138. DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis
139. Is Mycobacterium tuberculosis 15,000 years old?
140. Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance
141. Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2
142. Identification of the cystic fibrosis gene: Genetic analysis
143. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations
144. Early pulmonary inflammation in infants with cystic fibrosis
145. Nontuberculous mycobacteria in adult patients with cystic fibrosis
146. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis
147. Drug sensitivity of the Shigella strains isolated in 1955
148. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis
149. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis
150. In vivo nasal potential difference: Techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis
151. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7
152. Drug resistance to aminoglycosidic antibiotics in Pseudomonas aeruginosa and its lability
153. Benign missense variations in the cystic fibrosis gene
154. Diagnosis and treatment of cystic fibrosis
155. Therapies aimed at airway inflammation in cystic fibrosis
156. Effect of high-dose ibuprofen in patients with cystic fibrosis
157. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
158. Efficacy of the Flutter device for airway mucus clearance in patients with cystic fibrosis
159. DNA sequence and expression analysis of algP and algQ, components of the multigene system transcriptionally regulating mucoidy in Pseudomonas aeruginosa: algP contains multiple direct repeats
160. Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages
161. Terminal sialylation is altered in airway cells with impaired CFTR-mediated chloride transport
162. + currents by intracellular domains of the cystic fibrosis transmembrane conductance regulator
163. Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses
164. Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis
165. Darmverschluss dutch eingedicktes Meconium; pankreatitis
166. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa
167. Hypochlorite scavenging by Pseudomonas aeruginosa alginate
168. Mapping the surface regions of Pseudomonas aeruginosa PAK pilin: The importance of the C-terminal region for adherence to human buccal epithelial cells
169. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection
170. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients
171. Cyclic AMP-dependent protein kinase opens chloride channels in normal but not cystic fibrosis airway epithelium
172. Adenosine triphosphate-dependent asymmetry of anion permeation in the cystic fibrosis transmembrane conductance regulator chloride channel
173. Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions
174. Characterization of the adenosine triphosphatase activity of the periplasmic histidine permease, a traffic ATPase (ABC transporter)
175. Efflux pumps and drug resistance in Gram-negative bacteria
176. Function of the R domain in the cystic fibrosis transmembrane conductance regulator chloride channel
177. Phosphorylation-independent activity of the response regulators AlgB and AlgR in promoting alginate biosynthesis in mucoid Pseudomonas aeruginosa
178. Identification of the histidine protein kinase KinB in Pseudomonas aeruginosa and its phosphorylation of the alginate regulator AlgB
179. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis
180. Sequence and structural homology among membrane-associated domains of CFTR and certain transporter proteins
181. Surfactant protein A enhances alveolar macrophage phagocytosis of a live, mucoid strain of P. aeruginosa
182. Analysis of promoters controlled by the putative sigma factor AlgU regulating conversion to mucoidy in Pseudomonas aeruginosa: Relationship to sigma E and stress response
183. Outer membrane proteins responsible for multiple drug resistance in Pseudomonas aeruginosa
184. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: A mechanism for virulence activation in the cystic fibrosis lung
185. Posttranslational control of the algT (algU)-encoded sigma22 for expression of the alginate regulon in Pseudomonas aeruginosa and localization of its antagonist proteins MucA and MucB (AlgN)
186. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease
187. Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis
188. Cystic fibrosis of the pancreas in patients over 10 years of age
189. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo
190. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients
191. Heterozygotes for the delta F508 cystic fibrosis allele are not protected against bronchial asthma
192. Phagocytosis of mucoid and nonmucoid strains of Pseudomonas aeruginosa
193. Azlocillin with and without an aminoglycoside against respiratory tract infections in children with cystic fibrosis
194. Frequency of F116-mediated transduction of Pseudomonas aeruginosa in a freshwater environment
195. The effects of postural drainage and positive expiratory pressure physiotherapy on tracheobronchial clearance in cystic fibrosis
196. Skin reactivity to atypical mycobacteria in cystic fibrosis
197. Multiantibiotic resistance caused by active drug extrusion in Pseudomonas aeruginosa and other gram-negative bacteria
198. Syntaxin 1A is expressed in airway epithelial cells, where it modulates CFTR Cl(-) currents
199. Regulation of CFTR chloride channels by syntaxin and Munc18 isoforms
200. Identification of a cystic fibrosis mutation: Deletion of isoleucine506
201. Expression and characterization of the NBD1-R domain region of CFTR: Evidence for subunit-subunit interactions
202. Purification and characterization of HisP, the ATP-binding subunit of a traffic ATPase (ABC transporter), the histidine permease of Salmonella typhimurium. Solubility, dimerization, and ATPase activity
203. Role of alginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms
204. The pathogenesis of polycystic pancreas: Reconstruction of cystic elements in one case
205. Studies on inheritance of drug resistance between Shigella strains and Escherichia coli strains
206. Autoinducer-mediated regulation of rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa
207. Genetic mapping of chromosomal determinants for the production of the exopolysaccharide alginate in a Pseudomonas aeruginosa cystic fibrosis isolate
208. An R plasmid of Serratia marcescens transferable to Pseudomonas aeruginosa
209. Evolution and utility of a Pseudomonas aeruginosa drug resistance factor
210. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype
211. Exploitation of syndecan-1 shedding by Pseudomonas aeruginosa enhances virulence
212. Syndecan-1 shedding is enhanced by LasA, a secreted virulence factor of Pseudomonas aeruginosa
213. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication
214. A conserved region of the R domain of cystic fibrosis transmembrane conductance regulator is important in processing and function
215. Structure of the autoinducer required for expression of Pseudomonas aeruginosa virulence genes
216. A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa
217. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis
218. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?
219. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response
220. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre
221. Quinolone signaling in the cell-to-cell communication system of Pseudomonas aeruginosa
222. Self-administered chest physiotherapy in cystic fibrosis: A comparative study of highpressure PEP and autogenic drainage
223. Carbenicillin treatment of Pseudomonas pulmonary infection. Use in children with cystic fibrosis
224. Pulmonary disease associated with Pseudomonas aeruginosa in cystic fibrosis: Current status of the host-bacterium interaction
225. CFTR mutations and host susceptibility to Pseudomonas aeruginosa infection
226. Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement
227. Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis
228. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine
229. Salmonella typhi uses CFTR to enter intestinal epithelial cells
230. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung
231. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections
232. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older, non-colonized cystic fibrosis patients
233. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections
234. Studies on pulmonary secretions. 3. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy
235. Bicarbonate conductance and pH regulatory capability of cystic fibrosis transmembrane conductance regulator
236. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis
237. Phenotypic differences among clinically isolated mucoid Pseudomonas aeruginosa strains
238. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens
239. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis
240. Walker mutations reveal loose relationship between catalytic and channel-gating activities of purified CFTR (cystic fibrosis transmembrane conductance regulator)
241. Management of pulmonary disease in patients with cystic fibrosis
242. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis
243. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
244. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients
245. Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis
246. Failure of the cystic fibrosis transmembrane conductance regulator to conduct ATP
247. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
248. The cystic fibrosis transmembrane conductance regulator is a dual ATP and chloride channel
249. Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages
250. Mechanisms of drug resistance. The beta-lactamases of Gram-negative bacteria including pseudomonads
251. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines
252. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
253. Impaired stimulus-evoked mucus secretion in cystic fibrosis bronchi
254. Identification of the cystic fibrosis gene: Chromosome walking and jumping
255. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis
256. Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies
257. Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: Role of opsonizing anti-beta2-glycoprotein I antibodies
258. The selective engulfment of apoptotic bodies by dendritic cells is mediated by the alpha(v)beta3 integrin and requires intracellular and extracellular calcium
259. Pseudomonas aeruginosa pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells
260. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes
261. Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro
262. Potential for transduction of plasmids in a natural freshwater environment: Effect of plasmid donor concentration and a natural microbial community on transduction in Pseudomonas aeruginosa
263. Serum sensitivity of a Pseudomonas aeruginosa mucoid strain
264. Frequency of Aspergillus fumigatus isolates and antibodies to aspergillus antigens in cystic fibrosis
265. Autogenic drainage: A modern approach to physiotherapy in cystic fibrosis
266. Phosphorylation fails to activate chloride channels from cystic fibrosis airway cells
267. + channel
268. The cystic fibrosis transmembrane conductance regulator activates aquaporin 3 in airway epithelial cells
269. Aquaporin 3 cloned from xenopus laevis is regulated by the cystic fibrosis transmembrane conductance regulator
270. Protection against bronchial asthma by CFTR delta F508 mutation: A heterozygote advantage in cystic fibrosis
271. Transgenic cystic fibrosis mice exhibit reduced early clearance of Pseudomonas aeruginosa from the respiratory tract
272. 1 on epithelial cells
273. Micropuncture studies of the sweat formation in cystic fibrosis patients
274. Gene cluster controlling conversion to alginate-overproducing phenotype in Pseudomonas aeruginosa: Functional analysis in a heterologous host and role in the instability of mucoidy
275. The algD promoter: Regulation of alginate production by Pseudomonas aeruginosa in cystic fibrosis
276. Control of AlgU, a member of the sigma E-like family of stress sigma factors, by the negative regulators MucA and MucB and Pseudomonas aeruginosa conversion to mucoidy in cystic fibrosis
277. Frequency of the delta F508 mutation on cystic fibrosis chromosomes in Denmark
278. CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP
279. Both CFTR and outwardly rectifying chloride channels contribute to cAMP-stimulated whole cell chloride currents
280. G protein G alpha i-2 inhibits outwardly rectifying chloride channels in human airway epithelial cells
281. Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity
282. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
283. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis
284. Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis
285. Contribution of proline residues in the membrane-spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function
286. The purification and chemical characterisation of the alginate present in extracellular material produced by mucoid strains of Pseudomonas aeruginosa
287. Increased resistance to influenza as a possible source of heterozygote advantage in cystic fibrosis
288. An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton
289. - secretion in CF
290. CFTR upregulates the expression of the basolateral Na(+)-K(+)-2Cl(-) cotransporter in cultured pancreatic duct cells
291. Studies in cystic fibrosis: A report on sixty-five patients over 17 years of age
292. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms
293. Specific IgG subclass antibody pattern to Aspergillus fumigatus in patients with cystic fibrosis with allergic bronchopulmonary aspergillosis (ABPA)
294. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: Evidence of person-to-person transmission
295. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid
296. cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia
297. The in vivo effects of milrinone on the airways of cystic fibrosis mice and human subjects
298. Transferable drug resistance in Pseudomonas patients with premature rupture of membranes in Ile-Ife
299. Hospital epidemiology of Pseudomonas aeruginosa from patients with cystic fibrosis
300. Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis
301. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway
302. The diagnosis of cystic fibrosis
303. Pseudomonas aeruginosa lasR transcription correlates with the transcription of lasA, lasB, and toxA in chronic lung infections associated with cystic fibrosis
304. CFTR as a cAMP-dependent regulator of sodium channels
305. Regulation of C1-channels in normal and cystic fibrosis airway epithelial cells by extracellular ATP
306. Multiple modes of regulation of airway epithelial chloride secretion by extracellular ATP
307. CFTR C1-channel and CFTR-associated ATP channel: Distinct pores regulated by common gates
308. R plasmids among Gramnegative bacteria with multiple drug resistance isolated in a general hospital
309. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
310. A yeast metal resistance protein similar to human cystic fibrosis transmembrane conductance regulator (CFTR) and multidrug resistance-associated protein
311. - channel in CHO cells stably expressing the cystic fibrosis gene
312. The effect of chloride concentration on human neutrophil functions: Potential relevance to cystic fibrosis
313. Pseudomonas cepacia pulmonary infection in adults with cystic fibrosis: Is nosocomial acquisition occurring?
314. Chest physical therapy management of patients with cystic fibrosis. A meta-analysis
315. Non-tuberculous mycobacteria in cystic fibrosis
316. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection
317. Activity of abundant antimicrobials of the human airway
318. Antimicrobial peptides and proteins in the innate defense of the airway surface
319. Population analysis of the major mutation in cystic fibrosis
320. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker
321. Localization of Staphylococcus aureus in infected airways of patients with cystic fibrosis and in a cell culture model of S. aureus adherence
322. Respiratory mucin inhibits the opsonophagocytic killing of Pseudomonas aeruginosa
323. Localization of cystic fibrosis locus to human chromosome 7cen-q22
324. Who needs chest physiotherapy? Moving from anecdote to evidence
325. The ductular cell in pancreatic cystic fibrosis
326. Degradation of CFTR by the ubiquitin-proteasome pathway
327. Respiratory physiotherapy for cystic fibrosis
328. Dysfunction of CFTR bearing the delta F508 mutation
329. Apparent fusion of the TOL plasmid with the R91 drug resistance plasmid in Pseudomonas aeruginosa
330. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak
331. Cystic fibrosis decreases the apical membrane chloride permeability of monolayers cultured from cells of tracheal epithelium
332. Vitamin A deficiency predisposes to Staphylococcus aureus infection
333. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
334. CFTR activation: Additive effects of stimulatory and inhibitory phosphorylation sites in the R domain
335. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea
336. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations
337. Chloride channels in cystic fibrosis patients
338. Stimulation of CFTR activity by its phosphorylated R domain
339. Transcriptional analysis of the Pseudomonas aeruginosa genes algR, algB, and algD reveals a hierarchy of alginate gene expression which is modulated by algT
340. Genetic studies on cystic fibrosis in Hawaii
341. Biofilm resistance to antimicrobial agents
342. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon
343. Lung disease in cystic fibrosis-an updated concept
344. Genotype and phenotype in cystic fibrosis